Home › Rating Schedule › Hemic and Lymphatic Systems
Diagnostic Code 7724: Solitary plasmacytoma
Hemic and Lymphatic Systems · 38 CFR §4.117 · All codes in this system
| Evaluation criteria | Rating |
|---|---|
| Solitary plasmacytoma, when there is active disease or during a treatment phase | 100% |
| Note (1): A 100 percent evaluation shall continue beyond the cessation of any surgical therapy, radiation therapy, antineoplastic chemotherapy, or other therapeutic procedures (including autologous stem cell transplantation). Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of ยง 3.105(e) of this chapter. If there has been no recurrence, rate residuals under the appropriate diagnostic codes | |
| Note (2): Rate a solitary plasmacytoma that has developed into multiple myeloma as symptomatic multiple myeloma | |
| Note (3): Rate residuals of plasma cell dysplasia (e.g., thrombosis) and adverse effects of medical treatment (e.g., neuropathy) under the appropriate diagnostic codes | |
Use this rating
Open the combined ratings calculator with this percentage already entered, then add your other rated conditions:
Source: eCFR Title 38, 38 CFR §4.117, current as of 2026-11-05. Criteria text is the regulatory text, reproduced verbatim for reference; it is not legal advice.